First Trust中小型成长强度ETF FSGS 深 沪
等待开盘 05-14 09:30:00 美东时间
30.3403
-0.309
-1.01%
华盛通- 最 高30.3501
- 今 开30.35
- 成交量 300股
- 最 低 30.3403
- 昨 收 30.6498
- 总市值 2882.33万
- 52周最高 32.0754
- 市盈率 静 --
- 换手率 0.03%
- 52周最低 28.35
- 委 比 0.00%
- 总股本 95.00万
- 历史最高 32.5669
- 量 比 0.36
- 振 幅 0.03%
- 历史最低 9.9631
- 每 手 1
- 风险率 0.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
Travere Therapeutics (TVTX) on Wednesday announced the pricing of its underwritten offering of $475M aggregate principal amount of 0.50% convertible senior notes due 2032. The sale of the notes is exp...
05-07 13:05
Transcript: Biomarin Pharmaceutical Q1 2026 Earnings Conference Call
Biomarin Pharmaceutical (NASDAQ:BMRN) held its first-quarter earnings conferenc...
05-05 05:35
Maze Therapeutics publishes corporate presentation on genetics-driven kidney and metabolic disease pipeline
Maze Therapeutics publishes corporate presentation on genetics-driven kidney and metabolic disease pipeline Maze outlined a kidney- and metabolic-disease pipeline built around small-molecule precision medicines, led by APOL1 inhibitor MZE829 for APOL1-mediated kidney disease (AMKD). Initial Phase 2
04-22 12:27
Reported Earlier, Travere Therapeutics Wins FDA Approval Of FILSPARI For Focal Segmental Glomerulosclerosis Without Nephrotic Syndrome, Delivering 48% Proteinuria Reduction Vs 27% For Irbesartan In Phase 3 DUPLEX Study
FILSPARI indicated to reduce proteinuria in adults and children aged 8 years and older with FSGS who do not have nephrotic syndromeAdditional indication for FILSPARI expands total addressable population to more than
04-14 14:19
Maze Therapeutics' MZE829 Delivers First Clinical Proof-Of-Concept In APOL1-Mediated Kidney Disease With 61.8% Mean uACR Reduction In FSGS Subgroup
– At week 12, treatment with MZE829 resulted in a 35.6% mean uACR reduction in broad AMKD patients, 50% of the patients achieved a greater than 30% reduction in uACR, and treatment was well-tolerated –– The
03-25 19:09
Asia Fuel Oil-HSFO retains downside risk in ample supply
Asia Fuel Oil-HSFO retains downside risk in ample supply SINGAPORE, Feb 25 (Reuters) - Asia's high sulphur fuel oil (HSFO) market steadied on Wednesday after a recent pare-back, though downside risk still lingered amid expectations of ample supply. The prompt March-April timespread for 380-cst HSFO
02-25 18:11
Akebia’s Praliciguat FSGS Trial Moves Forward, Adding Optionality to the Kidney Pipeline
Akebia Therapeutics ($AKBA) announced an update on their ongoing clinical study...
02-11 00:30
2026美股生物科技板块怎么投资？杰富瑞：关注6大首选、7大潜力和5大并购目标
杰富瑞近日发布了关于 2026 年美股生物科技行业的展望报告，聚焦行业首选投资标的、被低估的潜力企业和潜在并购机会。
2025-12-25 15:40
Asia Fuel Oil-Spot differentials steady, HSFO cracks firm on volatile crude
SINGAPORE, Dec 17 (Reuters) - Spot differentials for the Asia fuel oil market were little changed on Wednesday, though high-sulphur fuel cracks inched higher amid volatile crude prices. Benchmarks for...
2025-12-17 18:30
BRIEF-Akebia Announces Establishment Of Rare Kidney Disease Pipeline
Dec 1 (Reuters) - Akebia Therapeutics Inc AKBA.O: AKEBIA ANNOUNCES ESTABLISHMENT OF RARE KIDNEY DISEASE PIPELINE AKEBIA THERAPEUTICS: ACQUIRES NEXT GENERATION TISSUE-TARGETED C3D-FACTOR H FUSION PROTE...
2025-12-01 21:21
